[HTML][HTML] The landscape of signaling pathways and proteasome inhibitors combinations in multiple myeloma
T Paradzik, C Bandini, E Mereu, M Labrador, E Taiana… - Cancers, 2021 - mdpi.com
… MM cell lines and patient samples resistant to bortezomib. … the combination of perifosine
with bortezomib blocks AKT and … synergistic to bortezomib [161,162], antimyeloma activity has …
with bortezomib blocks AKT and … synergistic to bortezomib [161,162], antimyeloma activity has …
[HTML][HTML] Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma
R Suzuki, Y Kitamura, Y Nakamura, H Akashi… - Oncotarget, 2020 - ncbi.nlm.nih.gov
… with bortezomib, lenalidomide, or other novel agents in multiple … cytotoxicity and apoptosis
in MM cell lines and myeloma … novel drugs showed significant anti-myeloma effects on MM …
in MM cell lines and myeloma … novel drugs showed significant anti-myeloma effects on MM …
[HTML][HTML] CDK9 inhibitors in multiple myeloma: a review of progress and perspectives
J Borowczak, K Szczerbowski, N Ahmadi, Ł Szylberg - Medical oncology, 2022 - Springer
… cytotoxicity in Doxorubicin-resistant, Lenalidomide-resistant and Bortezomib-resistant cell
lines… The subsequent in-vitro study showed that although significant anti-myeloma effects were …
lines… The subsequent in-vitro study showed that although significant anti-myeloma effects were …
[HTML][HTML] Disulfiram/copper markedly induced myeloma cell apoptosis through activation of JNK and intrinsic and extrinsic apoptosis pathways
Y Xu, Q Zhou, X Feng, Y Dai, Y Jiang, W Jiang… - Biomedicine & …, 2020 - Elsevier
… new drugs such as proteasome inhibitors (eg, bortezomib and … the toxicity of DSF or DSF/Cu
to the myeloma cell lines, we … DSF/Cu as a potent anti-myeloma agent in vitro and in animal …
to the myeloma cell lines, we … DSF/Cu as a potent anti-myeloma agent in vitro and in animal …
CDK9 inhibitors in multiple myeloma: a review of progress and perspectives
B Jędrzej, S Krzysztof, A Navid, S Łukasz - Medical Oncology, 2022 - search.proquest.com
… -resistant and Bortezomib-resistant cell lines. They seem to … in-vitro study showed that although
significant anti-myeloma effects … leukemia cells and has synergistic activity with perifosine …
significant anti-myeloma effects … leukemia cells and has synergistic activity with perifosine …
Emerging protein kinase inhibitors for the treatment of multiple myeloma
J Lind, F Czernilofsky, S Vallet… - … on Emerging Drugs, 2019 - Taylor & Francis
… perifosine in combination with lenalidomide and dexamethasone [Citation93], or … enzastaurin
and bortezomib in RRMM was well tolerated and demonstrated some antimyeloma activity […
and bortezomib in RRMM was well tolerated and demonstrated some antimyeloma activity […
Resistance to the proteasome inhibitors: Lessons from multiple myeloma and mantle cell lymphoma
M Gonzalez-Santamarta, G Quinet… - … and Disease: From …, 2020 - Springer
… , the proteasome inhibitor bortezomib (BTZ) significantly … inhibiting activity displayed promising
anti-myeloma activity [80]. … perifosine combined with BTZ revealed increase cytotoxicity …
anti-myeloma activity [80]. … perifosine combined with BTZ revealed increase cytotoxicity …
[HTML][HTML] Future developments in the treatment of AL amyloidosis
… In vitro, when AL plasma cell lines are exposed to LY-411575… combination treatments with
other anti-myeloma agents. It is … evaluated the combination of perifosine with bortezomib and …
other anti-myeloma agents. It is … evaluated the combination of perifosine with bortezomib and …
[HTML][HTML] Signaling pathway mediating myeloma cell growth and survival
T Hideshima, KC Anderson - Cancers, 2021 - mdpi.com
… perifosine induces significant cytotoxicity in MM cells which … TAS-117 enhances
bortezomib-induced cytotoxicity in vivo in … cytotoxicity in both MM cell lines and patient MM cells, …
bortezomib-induced cytotoxicity in vivo in … cytotoxicity in both MM cell lines and patient MM cells, …
[HTML][HTML] Pathway-directed therapy in multiple myeloma
… attributed to perifosine and might be at least partly due to lenalidomide [79]. … in vitro anti-myeloma
activity was induced by nutlin-3, and synergistic effects with melphalan and bortezomib …
activity was induced by nutlin-3, and synergistic effects with melphalan and bortezomib …